- Login
- Register
- Home/Current Issue
- About the journal
- Editorial board
- Online submission
- Instructions for authors
- Subscriptions
- Foundation Acta Endocrinologica
- Archive
- Contact
Romanian Academy
The Publishing House of the Romanian Academy
ACTA ENDOCRINOLOGICA (BUC)
The International Journal of Romanian Society of Endocrinology / Registered in 1938in Web of Science Master Journal List
Acta Endocrinologica(Bucharest) is live in PubMed Central
Journal Impact Factor - click here.
This Article
Services
Google Scholar
PubMed
Acta Endocrinologica (Buc)
Dumitrescu CP, Procopiuc C, Dumitriu N, Micle I, Anton M, Moisuc A
COMPLIA: a 12-Month Prospective, Multicentre, Non-Interventional Study to Evaluate Treatment Adherence and Treatment Satisfaction in a Growth Hormone Deficient Paediatric Population Treated with NutropinAq® a Somatropin Analogue
Acta Endo (Buc) 2020, 16 (2): 192-198doi: 10.4183/aeb.2020.192
Background/Aims. Growth hormone deficiency
(GHD) in children and adolescents is managed with growth
hormone (GH) therapy and aims to achieve optimal height
development. However, treatment adherence can be poor,
reducing the likelihood of a successful outcome. Adherence
varies between geographic regions. This observational
study assessed satisfaction and adherence to NutropinAq
(somatropin, recombinant human GH) treatment in
Romanian children with GHD.
Methods. Patients ≥3 years of age with GHD
for which GH replacement therapy with NutropinAq had
been initiated were recruited from 13 centres in Romania
(protocol number: A-38-58035-016). The primary variable
was patient/caregiver-reported treatment adherence
(assessed at 3, 6 and 12 months on a 5-item Likert scale),
secondary variables included treatment satisfaction
assessed by the treating physician and patient/caregiver on
a 5-point scale.
Results. Most patients did not miss any treatment
injections in any 3-month period between assessments
(≥79.8% of patients were 100% compliant). The incidence
of missed injections was higher among patients <7 years of
age than older children, but no differences between genders
was observed. At study end, 94.3% of patients/caregivers
and 94.3% of physicians reported complete satisfaction with
treatment.
Conclusions. Overall treatment adherence to
NutropinAq was high in the Romanian GHD paediatric
population, and a high level of treatment satisfaction was
reported by patients/caregivers. This suggests reliable
treatment outcomes can be anticipated in this population.
Keywords: Somatropin analogue, growth
hormone, NutropinAq®, growth hormone deficiency (GDH),
paediatric.
Correspondence: Armand Moisuc MD, Ipsen Pharma Romania SRL - Medical, Sapientei 17, bl 103A, ap 9, Bucharest, 050132,
Romania, E-mail: armand.moisuc@gmail.com